Tessellate Bio is supported by top-tier, global life science investors

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Boston and Germany
Forbion is a leading global venture capital firm with deep expertise in Europe. Forbion invests in innovative biotech companies, managing just over €5 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion’s current team consists of over 30 investment professionals that have built an impressive performance track record since the late nineties with 128 investments across 11 funds. Forbion selects impactful investments that will positively affect the health and well-being of people and the planet, as well as meet its financial return objectives. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.

BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies
The Company has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class companies. BGV manages over EUR 400 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together. BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realization for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.
BGV is the early-stage focused platform partner of Forbion, a leading European life sciences venture capital fund with €3 billion in capital under management, and is based in Naarden, The Netherlands.